Rx Bandz, LLC — Department of Defense SBIR Phase I: AF211-CSO1
Rx Bandz, LLC — SBIR Phase I award from Department of Defense.
- Amount
- $49,434
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AF211-CSO1
- Solicitation
- X21.1
- NAICS
- —
- Place of performance
- TX
- Period
- 2021-04-14 → 2021-07-19
Description
x Bandz’ innovative MiniJect™ auto-injector can be adapted to deliver epinephrine to Active Duty and beneficiaries prone to allergic reactions (anaphylaxis), as well as medics providing epinephrine when treating shock, cardiac arrest or respiratory distress. Its reduced size, weight, and ease-of-use means users can administer the right dose more reliably and quickly, no longer having to carry bulky, inconvenient auto-injectors. Furthermore, Rx Bandz’ epinephrine formulation aims to provide an increased shelf life over current auto-injectors.